23:47 , Jul 5, 2017 |  BC Extra  |  Company News

Management tracks

Regenacy Pharmaceuticals LLC (Boston, Mass.) named Simon Jones president and CEO. He was VP of biology at EPIX Pharmaceuticals Inc. (Pink:EPIX). Jones succeeds Walter Ogier, who will remain a director. Last December, Acetylon Pharmaceuticals Inc....
11:43 , Dec 1, 2016 |  BC Week In Review  |  Financial News

Essa Pharma completes debt financing

Essa drew down $8 million from a new $10 million term loan facility from Silicon Valley Bank. The loan bears interest at 3% plus the prime rate and matures on Sept. 1, 2020. The remaining...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Financial News

Essa Pharma completes private placement of units

Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C.   Business: Cancer   Date completed: 2016-01-14   Type: Private placement of units   Raised: $15 million   Units: 4.5 million   Price: $3.30 (unit)   Shares after...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Financial News

Essa Pharma proposes private placement of units

Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C.   Business: Cancer   Date announced: 2016-01-06   Type: Private placement of units   To be raised: About $15 million   Units: 4.5 million   Price: $3.30 (unit)...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

EPI-506: Phase I/II started

Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C.   Product: EPI-506   Business: Cancer   Molecular target: Androgen receptor   Description: Selective blocker of the N-terminus of the androgen receptor   Indication: Treat metastatic castration-resistant prostate...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

Vivus endocrine/metabolic news

Vivus investor First Manhattan Co. (FMC) said it plans to nominate a slate of six new directors to the biotech's board and urged Vivus to find a U.S. partner for obesity drug Qsymia phentermine/topiramate. In...
01:54 , Mar 9, 2013 |  BC Extra  |  Company News

FMC wants new Vivus board, strategy

Vivus Inc. (NASDAQ:VVUS) investor First Manhattan Co. (FMC) said it plans to nominate a slate of six new directors to the biotech's board and urged Vivus to find a U.S. partner for obesity drug Qsymia...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Company News

Amgen, Epix autoimmune news

Amgen will sell the assets of the partners' sphingosine 1-phosphate receptor 1 ( S1PR1 ; S1P1 ; EDG1 ) agonists program in a sealed bid sale on Dec. 8. Amgen said the decision was based...
07:00 , Aug 1, 2011 |  BC Week In Review  |  Clinical News

Naluzotan: Phase II started

Proximagen disclosed in its 2Q11 earnings that NIH's National Institute of Neurological Disorders and Stroke (NINDS) began a double-blind, placebo-controlled, crossover, U.S. Phase II trial to evaluate 120 mg oral naluzotan twice daily in about...
08:00 , Feb 28, 2011 |  BioCentury  |  Emerging Company Profile

Karyopharm: Shushing the usher

In the battle with the human body's natural defense mechanisms, one of the favorite tricks of tumor cells is to use karyopherins to usher tumor suppressor proteins outside the nucleus where they can no longer...